Monday, March 30, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

Pre-pandemic Trust and Mistrust in Americans’ Views of Scientific Experts

More Americans have confidence in scientists, but there are political divides over the role of scientific experts in policy issues

In an era when science and politics often appear to collide, public confidence in scientists is on the upswing, and six-in-ten Americans say scientists should play an active role in policy debates about scientific issues, according to a new Pew Research Center survey.

The survey finds public confidence in scientists on par with confidence in the military. It also exceeds the levels of public confidence in other groups and institutions, including the media, business leaders and elected officials.

At the same time, Pre-pandemic Americans are divided along party lines in terms of how they view the value and objectivity of scientists and their ability to act in the public interest. And, while political divides do not carry over to views of all scientists and scientific issues, there are particularly sizable gaps between Democrats and Republicans when it comes to trust in scientists whose work is related to the environment.

Confidence in scientists is stronger among those with high science knowledge and among DemocratsHigher levels of familiarity with the work of scientists are associated with more positive and more trusting views of scientists regarding their competence, credibility and commitment to the public, the survey shows.

Source: Pews Research

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

Policy Shift in Peptide Regulation

Semaglutide and the Expansion Problem: When One Trial Becomes a Platform

Semaglutide and the Expansion Problem: When One Trial Becomes a Platform

Semaglutide has moved beyond its original indication and now sits at the center of a widening set of clinical questions: cardiovascular risk, kidney disease progression, and even neurodegeneration. The question is no longer whether the drug lowers glucose or reduces weight—it does—but how far those effects extend across systems, and whether evidence from one population can be translated into another without distortion. Large, well-powered trials have produced consistent signals, yet those signals are now being applied in contexts that were...

Read more

Join Our Newsletter!